When you’re in the middle of a crisis like the COVID-19 pandemic, getting timely test results is imperative. Unfortunately, laboratory testing does not scale well due to its centralized testing infrastructure. It also requires sample transportation, complicated equipment, and technical expertise, all of which lead to high costs and time delays that are incompatible with problems that require immediate answers. Today on the show, we talk with Khalid Alam, Founder and CEO of Stemloop, a privately-held company that is currently focused on developing cell-free biosensors to solve challenges in biomanufacturing, environmental monitoring, and human health. Tuning in, you’ll learn more about Khalid’s career, how he became interested in biochemistry and biotech, and how Stemloop’s cell-free biosensors will monitor and fortify water supplies around the world. We discuss how the biotech space has evolved over the past few decades, why doing projects at scale is so beneficial, and how the cost of DNA sequencing has plummeted in recent years. Khalid also delves into the crisis that the US is currently experiencing with lead in their water supply, the challenges of solving this problem, and the rapid tests that Stemloop is building for household taps. Today’s episode offers an exciting look into the world of testing and is full of important insights on advancements in biotech. Tune in to hear it all!
“Two and a half years ago, when I was pitching Stemloop, I would tell people that laboratory testing doesn’t scale. I think they understood that superficially, but they didn’t necessarily empathize with it deeply.” — @BioChemPHD Key Points from this EpisodeEn liten tjänst av I'm With Friends. Finns även på engelska.